Mobile Screening Unit (MSU) for the Implementation of the 'Screen and Treat' Programme for Cervical Cancer Prevention In Pune, India.
Cervical cancer
Screening
Thermal ablation
mobile screening unit
Journal
Asian Pacific journal of cancer prevention : APJCP
ISSN: 2476-762X
Titre abrégé: Asian Pac J Cancer Prev
Pays: Thailand
ID NLM: 101130625
Informations de publication
Date de publication:
01 Feb 2021
01 Feb 2021
Historique:
received:
09
09
2020
entrez:
28
2
2021
pubmed:
1
3
2021
medline:
9
11
2021
Statut:
epublish
Résumé
We are reporting the evaluation of an opportunistic point of care cervical cancer screening initiative in Pune, India using a mobile screening unit (MSU). We conducted 290 cervical cancer screening outreach clinics in the MSU. Screening was performed by trained nurses/ health care providers using visual inspection with 5% acetic acid (VIA). Screen positive women when eligible were treated by thermal ablation during the same sitting. Women with large lesions not eligible for treatment with thermal ablation were referred for colposcopy and treatment. A total of 10, 925 women were screened between Nov 2016 and June 2019 in 290 outreach clinics in the MSU. The overall screen positivity was 6.6% (95% CI 6.1, 7.0) with a declining trend over time. A total of 304/717 (42.4%, 95% CI 38.7, 46.1) women received treatment with thermal ablation. About 3.6% (11/304) reported minor side effects and 1.6% (5/304) reported lower abdominal pain and all of them subsided after treatment. Among the 413 women who were advised colposcopy, only 84 (20.33%) women underwent the procedure. Of these 84 women, 64 (76.19%) had normal colposcopy/ histopathology, 7 (8.33%) had CIN1, 2 (2.38%) had CIN 2, 9 (10.71%) had CIN 3 disease and 2 (2.38%) women were diagnosed with invasive cancer. MSUs are useful for providing cervical cancer screening services, using the 'screen and treat' strategy. Thermal ablation is safe in the field clinics. Additional efforts are needed to improve the compliance for referral of those with large lesions requiring additional visits.
Identifiants
pubmed: 33639655
doi: 10.31557/APJCP.2021.22.2.413
pmc: PMC8190336
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
413-418Références
Eur J Cancer. 2009 Oct;45(15):2640-8
pubmed: 19695864
BMC Cancer. 2019 Apr 5;19(1):317
pubmed: 30952209
Lancet Oncol. 2020 Apr;21(4):467
pubmed: 32240603
AIDS. 2013 Feb 20;27(4):607-15
pubmed: 23079814
Int J Gynaecol Obstet. 2016 Mar;132(3):252-8
pubmed: 26868062
Asian Pac J Cancer Prev. 2011;12(7):1681-5
pubmed: 22126544
JMIR Med Inform. 2018 Mar 01;6(1):e13
pubmed: 29496651
Cancer Epidemiol Biomarkers Prev. 2017 Dec;26(12):1679-1694
pubmed: 28978564
Int J Womens Health. 2015 May 04;7:477-83
pubmed: 25999765
J Clin Diagn Res. 2014 Jun;8(6):OC01-3
pubmed: 25121031
MMWR Morb Mortal Wkly Rep. 2019 Jan 11;68(1):14-19
pubmed: 30629571
J Med Syst. 2016 Jan;40(1):14
pubmed: 26573651
PLoS One. 2015 Apr 17;10(4):e0122169
pubmed: 25885821
Lancet Oncol. 2020 Jan;21(1):175-184
pubmed: 31734069
Cancer. 2017 Jul 1;123(13):2387-2388
pubmed: 28621905
Prev Med. 2019 Jan;118:81-91
pubmed: 30342109
Public Health Rep. 1965 Jul;80:633-6
pubmed: 14310589
J Obstet Gynaecol Res. 2020 Feb;46(2):320-327
pubmed: 31814247
PLoS Med. 2008 Jun 17;5(6):e132
pubmed: 18563963
Lancet Glob Health. 2020 Feb;8(2):e191-e203
pubmed: 31812369
Int J Gynaecol Obstet. 2005 May;89 Suppl 2:S4-S12
pubmed: 15823266
Lancet Oncol. 2019 Mar;20(3):394-407
pubmed: 30795950
Indian J Community Med. 2015 Jul-Sep;40(3):203-7
pubmed: 26170547